Literature DB >> 24336633

The translational potential for target validation and therapy using intracellular antibodies in oncology.

Ulrich H Weidle1, Daniela Maisel, Ulrich Brinkmann, Georg Tiefenthaler.   

Abstract

Antibody-based molecules can be delivered into cells either by intracellular expression or through cellular uptake. We describe technologies for identification and expression of intracellular antibodies for target validation, intracellular immunization and tumor therapy, such as intracellular antibody capture technology, suicide or silencing technology, antigen-antibody interaction dependent apoptosis and their application for inhibition of oncogenic intracellular proteins and induction of apoptosis. These strategies have to be viewed in the context that inhibition of protein-protein interactions by small molecules is often limited due to their large interaction surface. We summarize antibodies with the ability to penetrate cells and strategies to induce uptake of antibodies after modification with protein transduction domains. Interference in oncogenic pathways is described for moieties based on antibody 3E10, which translocates into the nucleus after extracellular administration. Finally, we discuss examples of tumor immunotherapy and vaccination against intracellular antigens, and possible interactions mediating their mode of action.

Entities:  

Keywords:  Autoimmune disease-related antibodies; cancer immunotherapy against intracellular targets; inhibition of oncogenic pathways; intracellular immunization; mechanisms of antibody uptake; protein knock-down; protein transduction domain; review; target validation

Mesh:

Substances:

Year:  2013        PMID: 24336633

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  9 in total

1.  MNT Optimization for Intracellular Delivery of Antibody Fragments.

Authors:  A V Ulasov; Y V Khramtsov; T N Lupanova; A D Tsvetkova; A A Rosenkranz; T A Slastnikova; G P Georgiev; A S Sobolev
Journal:  Dokl Biochem Biophys       Date:  2018-05-19       Impact factor: 0.788

2.  PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Authors:  Min Thura; Abdul Qader Omer Al-Aidaroos; Wei Peng Yong; Koji Kono; Abhishek Gupta; You Bin Lin; Kousaku Mimura; Jean Paul Thiery; Boon Cher Goh; Patrick Tan; Ross Soo; Cheng William Hong; Lingzhi Wang; Suling Joyce Lin; Elya Chen; Sun Young Rha; Hyun Cheol Chung; Jie Li; Sayantani Nandi; Hiu Fung Yuen; Shu-Dong Zhang; Yeoh Khay Guan; Jimmy So; Qi Zeng
Journal:  JCI Insight       Date:  2016-06-16

3.  A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models.

Authors:  Carla Amici; Michela Visintin; Francesca Verachi; Francesca Paolini; Zulema Percario; Paola Di Bonito; Angela Mandarino; Elisabetta Affabris; Aldo Venuti; Luisa Accardi
Journal:  Oncotarget       Date:  2016-03-29

4.  Intracellular delivery of antibodies by chimeric Sesbania mosaic virus (SeMV) virus like particles.

Authors:  Ambily Abraham; Usha Natraj; Anjali A Karande; Ashutosh Gulati; Mathur R N Murthy; Sathyabalan Murugesan; Pavithra Mukunda; Handanahal S Savithri
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

Review 5.  Therapeutic Antibodies against Intracellular Tumor Antigens.

Authors:  Iva Trenevska; Demin Li; Alison H Banham
Journal:  Front Immunol       Date:  2017-08-18       Impact factor: 7.561

Review 6.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

Review 7.  Opportunities and Challenges for Antibodies against Intracellular Antigens.

Authors:  Xiaofeng Yang; Shenxia Xie; Xiaomei Yang; Juan C Cueva; Xiaoqiong Hou; Zhuoran Tang; Hua Yao; Fengzhen Mo; Shihua Yin; Aiqun Liu; Xiaoling Lu
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

8.  RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.

Authors:  Laura Mandik-Nayak; James B DuHadaway; Jennifer Mulgrew; Elizabeth Pigott; Kaylend Manley; Summer Sedano; George C Prendergast; Lisa D Laury-Kleintop
Journal:  Dis Model Mech       Date:  2017-09-07       Impact factor: 5.758

9.  In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant KRAS antigens.

Authors:  Allan Wee Ren Ng; Pei Jun Tan; Winfrey Pui Yee Hoo; Lionel Lian Aun In; Dek Shen Liew; Michelle Yee Mun Teo; Pui Yan Siak; Sze Man Ng; Ee Wern Tan; Raha Abdul Rahim; Renee Lay Hong Lim; Adelene Ai Lian Song
Journal:  PeerJ       Date:  2018-07-20       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.